There are positive results from the Phase III study of TECENTRIQ, OAK according to Genentech, Inc. Having met its co-primary endpoints and in comparison with docetaxel chemotherapy in people with non-small cell lung cancer (NSCLC), the overall survival (OS) had notable statistical, significant and meaningful improvement. The NSCLC usually progresses even after treatment with platinum-based chemotherapy, but there have been consistent adverse events with TECENTRIQ. With all this development, Genentech which is a member of the Roche Group is to some extent optimistic of being able to present results from the Phase III study.
TECENTRIQ has obtained a Breakthrough Therapy Designation (BTD) from the FDA to be used in the treatment of people with PD-L1 positive NSCLC. Sandra Horning, M.D., chief medical officer and head of Global Product Development says that the results are appealing. Evidently, they will add to the growing evidence that TECENTRIQ is a potential new treatment for certain kinds of advanced NSCLC. Horning emphasizes that the news is encouraging especially to those living with NSCLC. It is an option of treatment for lung cancer which is the leading cause of cancer deaths.
The use of TECENTRIQ and its side effects
Its primary efficacy was achieved from analysis of first 850 randomized patients while the secondary efficacy analysis included 1,225 randomized patients. It is a prescription for treating a type of bladder cancer called urothelial carcinoma and more so when it has spread or cannot be removed by surgery. It can also be used in case of failure of chemotherapy. Nonetheless, ineffectiveness in children has not been established as yet.
TECENTRIQ has a series of side effects. It can easily cause the immune system to attack healthy organs and tissues. The problem can be life-threatening hence immediate medical attention is of the essence. Other side effects include decreased appetite, urinary tract infection, constipation and fever, nausea, feeling tired among others. Of caution is to seek the assistance of a healthcare provider before any attempt to use it.
Here’s What Life Clips Inc (OTCMKTS:LCLP), Retail Ready Group Are Up To
Life Clips Inc (OTCMKTS:LCLP) has managed to add Retail Ready Group to its rapidly expanding network of third-party distributors.
The agreement that Life Clips Inc (OTCMKTS:LCLP) and Retail Ready have entered into gives the distributor exclusive rights to distribute certain products of Life Clips. The products covered under the agreement are Life Clips’ 4K action camera and Mobeego product.
Though Life Clips already has other distribution arrangements for these products, only Retail Ready will distribute them to Home Depot Inc (NYSE:HD), GameStop Corp. (NYSE:GME), Lowe’s Companies, Inc. (NYSE:LOW) and 7-Eleven.
Keep in mind that Retail Ready is a global distributor that serves some of the largest retailers in the world. Outside the already named retailers served by Retail Ready, the distributors other retail customers are J C Penney Company Inc (NYSE:JCP), Academy Sports, Battery’s Plus and many others.
It is no wonder that the management of Life Clips Inc (OTCMKTS:LCLP) feels excited to have management to work with the experience team at Retail Ready to fly their brand flag. Life Clips’ CEO, Bob Gruder, commented that the deal with Retail Ready is consistent with their efforts to expand in the U.S. and internationally.
